The discovery and development of pharmaceuticals that target the genetic cause of CF by attaching and inserting into the CFTR and forcing it into the open functional form, thereby increasing ion transport across the CFTR, are showing great promise in relieving the effects of CF. The gene discussed is CFTR; the disease is cystic fibrosis.